Bayer is investing $115m in a partnership with Arvinas, aimed at developing the biotech firm's protein degradation technology Proteolysis-Targeting Chimera (PROTAC), for use in human and agricultural products. The company has already developed ProTAC to treat bacterial infections caused by Staphylococcus aureus (MRSA), which can cause skin infections, urinary tract infection (UTI) or meningitis.
Bayer is investing $115m in a partnership with Arvinas, aimed at developing the biotech firm's protein degradation technology Proteolysis-Targeting Chimera (PROTAC), for use in human and agricultural products. The companies will also work together to develop new agricultural products; they plan to use PROTAC to eliminate a protein linked to a disease by tagging it with engineered molecules.